Feed Preview

Going Viral

Alzheimer's Disease: Neuroimaging

Alzheimer's Disease: Neuroimaging diagram by Health and Human Services Department, National Institutes of Health, National Institute on Aging (Public Domain)
Health and Human Services Department, National Institutes of Health, National Institute on Aging (Public Domain)

Alzheimer's disease (AD) is a chronic neurodegenerative disease. Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Top 20 most recent papers
Neurology

Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition

NeurologyNovember 12, 2019
Jonathan Graff-RadfordClifford R. Jack
4
Journal of the American Chemical Society

Amyloid Protein-Induced Supramolecular Self-Assembly of Water-Soluble Platinum(II) Complexes: A Luminescence Assay for Amyloid Fibrillation Detection and Inhibitor Screening

Journal of the American Chemical SocietyNovember 11, 2019
Angela Sin-Yee LawVivian Wing-Wah Yam
bioRxiv

Exploring Survival Models Associated with MCI to AD Conversion: A Machine Learning Approach

bioRxivNovember 11, 2019
Jorge Orozco-SanchezJose Gerardo Tamez-Pena
5
Biosensors & Bioelectronics

A simple aptasensor for Aβ40 oligomers based on tunable mismatched base pairs of dsDNA and graphene oxide

Biosensors & BioelectronicsNovember 4, 2019
Yana ZhaoHuiyun Wu
Annals of Neurology

Lipid lowering and Alzheimer's disease risk: a Mendelian randomization study

Annals of NeurologyNovember 12, 2019
Dylan M. WilliamsAroon Dinesh Hingorani
8
JAMA Neurology

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial

JAMA NeurologyNovember 11, 2019
Richard M TsaiAdam L. Boxer
14
1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

Evaluation of dosimetry, quantitative methods and test-retest variability of 18 F-PI-2620 PET for the assessment of tau deposits in the human brain

Journal of Nuclear Medicine : Official Publication, Society of Nuclear MedicineNovember 11, 2019
Santiago BullichAndrew W Stephens
1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

Tau PET imaging with 18 F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study

Journal of Nuclear Medicine : Official Publication, Society of Nuclear MedicineNovember 11, 2019
Andre MuellerAndrew W Stephens
1
Journal of Magnetic Resonance Imaging : JMRI

Parametric Hemodynamic 4D Flow MRI Maps for the Characterization of Chronic Thoracic Descending Aortic Dissection

Journal of Magnetic Resonance Imaging : JMRINovember 12, 2019
Kelly B JarvisMichael Markl
Annals of Clinical and Translational Neurology

Study partner-reported decline identifies cognitive decline and dementia risk

Annals of Clinical and Translational NeurologyNovember 13, 2019
Rachel L NoshenyAlzheimer’s Disease Neuroimaging Initiative investigators
Annals of Neurology

Midlife atherosclerosis and development of Alzheimer's or vascular dementia

Annals of NeurologyNovember 12, 2019
Anna-Märta GustavssonOskar Hansson
4
Alzheimer's & Dementia : Translational Research & Clinical Interventions

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial

Alzheimer's & Dementia : Translational Research & Clinical InterventionsOctober 28, 2019
Daniel K BurnsAnn Marie Saunders
NeuroImage. Clinical

Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden

NeuroImage. ClinicalOctober 22, 2019
Aaron P SchultzJasmeer P Chhatwal
Neurobiology of Aging

White matter hyperintensities mediate the association between blood-brain barrier leakage and information processing speed

Neurobiology of AgingSeptember 27, 2019
Whitney M FreezeWalter H. Backes
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials

The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric PsychiatryOctober 1, 2019
George Thomas GrossbergJeffrey L. Cummings
EMBO Molecular Medicine

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

EMBO Molecular MedicineNovember 11, 2019
Sebastian PalmqvistOskar Hansson
11
Neurobiology of Aging

Amyloid burden and white matter hyperintensities mediate age-related cognitive differences

Neurobiology of AgingAugust 31, 2019
Pénélope S DupontSven Joubert
Alzheimer Disease and Associated Disorders

Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument

Alzheimer Disease and Associated DisordersNovember 13, 2019
Gabriela M MorrisJohn Carl Morris
bioRxiv

A/T/N polygenic risk score for cognitive decline in old age

bioRxivNovember 12, 2019
Annah M. MooreTimothy J. Hohman
23
International Journal of Biological Macromolecules

Polysaccharides from Lycium barbarum ameliorate amyloid pathology and cognitive functions in APP/PS1 transgenic mice

International Journal of Biological MacromoleculesNovember 9, 2019
Yue ZhouGang Pei
1

See more papers from this feed

Related Feeds

AFM in situ DNA

AFM in situ DNA describes in situ analysis (or study) of DNA using atomic force microscopy. Discover the latest research on AFM in situ DNA here.

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

© 2019 Meta ULC. All rights reserved
/feed-previews/alzheimers-disease-neuroimaging/a5242adb-290c-4f90-bd45-b0d1bbfc9166